86 related articles for article (PubMed ID: 36240849)
21. Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment.
Ratti M; Orlandi E; Hahne JC; Vecchia S; Citterio C; Anselmi E; Toscani I; Ghidini M
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37893023
[TBL] [Abstract][Full Text] [Related]
22. Genomic landscape of clinically advanced
Ashok Kumar P; Serinelli S; Zaccarini DJ; Huang R; Danziger N; Janovitz T; Basnet A; Sivapiragasam A; Graziano S; Ross JS
Front Oncol; 2023; 13():1169586. PubMed ID: 37404765
[TBL] [Abstract][Full Text] [Related]
23. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.
Matsuda Y; Yoshimura H; Suzuki T; Uchida E; Naito Z; Ishiwata T
Cancer Sci; 2014 Sep; 105(9):1212-9. PubMed ID: 24975163
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
26. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?
Helal C; Valéry M; Ducreux M; Hollebecque A; Smolenschi C
Eur J Cancer; 2022 Nov; 176():168-170. PubMed ID: 36244195
[No Abstract] [Full Text] [Related]
27. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
29. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
30. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK; Perry JB; Abdul-Rahim O; Frankel AE; Cameron D; Taylor W; Rocconi RP; Abushahin L; Nelson C; Singh AP; Khushman M
J Cancer Res Ther; 2020; 16(4):950-954. PubMed ID: 32930150
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]